Amit Munshi has more than $300M and a startup CSO out to pioneer next-gen RNA therapeutics. Once again, he’s thinking big
Amit Munshi had to beg off when he was first introduced to the idea of running an MPM BioImpact stealth player named ReNAgade Therapeutics. He had just sold Arena to Pfizer for $6.7 billion — a deal that wrapped in the spring of last year — after getting a lot of credit for turning the biotech around. And he was a hot commodity.
But first, before jumping back into the biotech forge of making new drugs, Munshi tells me, he wanted to spend some time with his aging parents in Houston, and his wife had the same idea, which took them to Bangkok. Munshi calls it all part of life’s deferred maintenance.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.